AIM: To investigate whether NF-kappaB is activated in human gastric carcinoma tissues and, if so, to study whether there is any correlation between NF-kappaB activity and heparanase expression in gastric carcinoma. METHODS: NF-kappaB activation was assayed by immunohistochemical staining in formalin-fixed, paraffin-embedded specimens from 45 gastric carcinoma patients. Electrophoretic mobility shift assay (EMSA) method was used for nuclear protein from these fresh tissue specimens. Heparanase gene expression was quantified using quantitative RT-PCR. RESULTS: The nuclear translocation of RelA (marker of NF-kappaB activation) was significantly higher in tumor cells compared to adjacent and normal epithelial cells ((41.3+/-3.52)% vs (0.38+/-0.22) %, t = 10.993, P = 0.000<0.05; (41.3+/-3.52)% vs (0+/-0.31)%, t = 11.484, P = 0.000<0.05). NF-kappaB activation was correlated with tumor invasion-related clinicopathological features such as lymphatic invasion, pathological stage, and depth of invasion (Z = 2.148, P = 0.032<0.05; chi(2) = 8.758, P = 0.033<0.05; chi(2) = 18.531, P = 0.006<0.05). NF-kappaB activation was significantly correlated with expression of heparanase gene (r = 0.194, P = 0.046<0.05). CONCLUSION: NF-kappaB RelA (p65) activation was related with increased heparanase gene expression and correlated with poor clinicopathological characteristics in gastric cancers. This suggests NF-kappaB as a major controller of the metastatic phenotype through its reciprocal regulation of some metastasis-related genes.
AIM: To investigate whether NF-kappaB is activated in humangastric carcinoma tissues and, if so, to study whether there is any correlation between NF-kappaB activity and heparanase expression in gastric carcinoma. METHODS:NF-kappaB activation was assayed by immunohistochemical staining in formalin-fixed, paraffin-embedded specimens from 45 gastric carcinomapatients. Electrophoretic mobility shift assay (EMSA) method was used for nuclear protein from these fresh tissue specimens. Heparanase gene expression was quantified using quantitative RT-PCR. RESULTS: The nuclear translocation of RelA (marker of NF-kappaB activation) was significantly higher in tumor cells compared to adjacent and normal epithelial cells ((41.3+/-3.52)% vs (0.38+/-0.22) %, t = 10.993, P = 0.000<0.05; (41.3+/-3.52)% vs (0+/-0.31)%, t = 11.484, P = 0.000<0.05). NF-kappaB activation was correlated with tumor invasion-related clinicopathological features such as lymphatic invasion, pathological stage, and depth of invasion (Z = 2.148, P = 0.032<0.05; chi(2) = 8.758, P = 0.033<0.05; chi(2) = 18.531, P = 0.006<0.05). NF-kappaB activation was significantly correlated with expression of heparanase gene (r = 0.194, P = 0.046<0.05). CONCLUSION:NF-kappaBRelA (p65) activation was related with increased heparanase gene expression and correlated with poor clinicopathological characteristics in gastric cancers. This suggests NF-kappaB as a major controller of the metastatic phenotype through its reciprocal regulation of some metastasis-related genes.
Authors: N Sasaki; T Morisaki; K Hashizume; T Yao; M Tsuneyoshi; H Noshiro; K Nakamura; T Yamanaka; A Uchiyama; M Tanaka; M Katano Journal: Clin Cancer Res Date: 2001-12 Impact factor: 12.531
Authors: L A Ries; P A Wingo; D S Miller; H L Howe; H K Weir; H M Rosenberg; S W Vernon; K Cronin; B K Edwards Journal: Cancer Date: 2000-05-15 Impact factor: 6.860
Authors: Yi Huang; Yong Fang; Jinmin Wu; Jennifer M Dziadyk; Xueming Zhu; Meihua Sui; Weimin Fan Journal: Mol Cancer Ther Date: 2004-03 Impact factor: 6.261
Authors: Vishnu C Ramani; Israel Vlodavsky; Mary Ng; Yi Zhang; Paola Barbieri; Alessandro Noseda; Ralph D Sanderson Journal: Matrix Biol Date: 2016-03-22 Impact factor: 11.583
Authors: Y Yang; C Gorzelanny; A T Bauer; N Halter; D Komljenovic; T Bäuerle; L Borsig; M Roblek; S W Schneider Journal: Oncogene Date: 2015-03-09 Impact factor: 9.867
Authors: Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan Journal: Drug Resist Updat Date: 2016-10-06 Impact factor: 18.500
Authors: R C Turkington; C Purcell; C R James; J Millar; E Napier; D Law; R Gallagher; M Morris; R H Wilson; M M Eatock Journal: Invest New Drugs Date: 2013-05-11 Impact factor: 3.850
Authors: W Weichert; M Boehm; V Gekeler; M Bahra; J Langrehr; P Neuhaus; C Denkert; G Imre; C Weller; H-P Hofmann; S Niesporek; J Jacob; M Dietel; C Scheidereit; G Kristiansen Journal: Br J Cancer Date: 2007-07-10 Impact factor: 7.640
Authors: Satvik R Hadigal; Alex M Agelidis; Ghadah A Karasneh; Thessicar E Antoine; Abraam M Yakoub; Vishnu C Ramani; Ali R Djalilian; Ralph D Sanderson; Deepak Shukla Journal: Nat Commun Date: 2015-04-27 Impact factor: 14.919